Brawn Biotech Intrinsic Value
BRAWN Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹41.36 | ₹33.09 - ₹49.63 | +79.9% | EPS: ₹1.88, Sector P/E: 22x |
| Book Value Method | asset | ₹20.00 | ₹18.00 - ₹22.00 | -13.0% | Book Value/Share: ₹10.00, P/B: 2.0x |
| PEG Ratio Method | growth | ₹12.03 | ₹10.83 - ₹13.23 | -47.7% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹29.05 | ₹26.14 - ₹31.96 | +26.4% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| Graham Defensive Method | conservative | ₹20.00 | ₹18.00 - ₹22.00 | -13.0% | EPS: ₹1.88, BVPS: ₹10.00 |
Want to compare with current market value? Check BRAWN share price latest .
Valuation Comparison Chart
BRAWN Intrinsic Value Analysis
What is the intrinsic value of BRAWN?
Based on our comprehensive analysis using 5 different valuation methods, the estimated intrinsic value of Brawn Biotech (BRAWN) is ₹20.00 (median value). With the current market price of ₹22.99, this represents a -13.0% variance from our estimated fair value.
The valuation range spans from ₹12.03 to ₹41.36, indicating ₹12.03 - ₹41.36.
Is BRAWN undervalued or overvalued?
Based on our multi-method analysis, Brawn Biotech (BRAWN) appears to be trading above median value by approximately 13.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 2.25 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 7.00 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Operating Margin | 25.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
Related Pages for Brawn Biotech
Additional stock information and data for BRAWN
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |